CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Although the MYSTIC phase 3 clinical trial examining durvalumab therapy for non–small-cell lung cancer (NSCLC) did not meet its primary end points – overall survival (OS) and progression-free survival (PFS) – it did show a numerically reduced risk for death with durvalumab (Imfinzi) versus chemotherapy in patients with PD-L1 expression on ≥25% of tumor cells.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
